Company Filing History:
Years Active: 2011-2015
Title: An Overview of Inventor Woodruff Emlen
Introduction
Woodruff Emlen, based in Greenwood Village, Colorado, is a notable inventor recognized for his contributions to the field of biomedical innovations. With two patents to his name, Emlen has made significant strides in developing novel approaches to treating diseases linked to the alternative complement pathway.
Latest Patents
Emlen's recent inventions include the humaneered anti-factor B antibody, which focuses on reducing immunogenicity. This innovative antibody and its antigen-binding fragments are derived from murine monoclonal antibody 1379. They specifically bind to factor B in the third short consensus repeat (SCR) domain. By selectively inhibiting the activation of the alternative complement pathway, this invention plays a crucial role in preventing the formation of the C3bBb complex. Furthermore, it presents potential methods for addressing diseases or disorders related to this pathway, offering new treatment avenues for individuals in need.
Career Highlights
Throughout his career, Woodruff Emlen has contributed to prestigious companies such as Taligen Therapeutics, Inc. and Alexion Pharmaceuticals, Inc. His work in these organizations has been fundamental in advancing therapeutic developments and enhancing the understanding of the complement system in disease.
Collaborations
Emlen has also collaborated with distinguished professionals in the field, notably V. Michael Holers and Peter Flynn. These partnerships have enriched his research and innovation, fostering a collaborative spirit that is essential in biomedical advancements.
Conclusion
In summary, Woodruff Emlen's contributions to the field of immunology through his patents and collaborative efforts reflect his commitment to innovation. His work not only enhances therapeutic strategies but also offers hope for treating conditions that affect many individuals globally.